VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2023 | HER2DX risk-score in early-stage HER2-positive breast cancer

Guillermo Villacampa Javierre, SOLTI – Groupo Espanol de Estudio, Barcelona, Spain, discusses the evaluation of the HER2DX risk-score in patients with early-stage HER2-positive breast cancer. The study utilized data from the latest release of the SCAN-B HER2+ cohort, with a larger sample size, longer follow-up, and treatment information. The HER2DX risk-score was found to be associated with overall survival (OS) as a continuous variable and using predefined cut-offs. The risk-score remained predictive of OS even after adjusting for clinical variables and treatment regimen. In patients with T1N0 tumors, the HER2DX high-risk group had inferior OS compared to the low-risk group. The HER2DX risk-score provides valuable prognostic information beyond traditional clinical-pathological factors in early-stage HER2-positive breast cancer patients. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter